With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
Metastatic renal cell carcinoma (RCC) was one of the earliest benefactors of immunotherapies, but there’s still room for improvement. A pilot study published this week in Clinical Cancer Research evaluated the immunogenicity of 15 Gy x 1 to the primary tumor (with 5mm margin) just prior to nephrectomy. SBRT produced an increase in tumor-associated antigens and modulated immune infiltrate--curbing two frequent barriers to optimal immunotherapy response. This adds to a growing body of evidence that radiation may be a key ingredient to future cancer vaccines.